{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T11:10:40Z","timestamp":1789989040168,"version":"4.0.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2018,3,12]],"date-time":"2018-03-12T00:00:00Z","timestamp":1520812800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1007\/s00259-018-3971-x","type":"journal-article","created":{"date-parts":[[2018,3,12]],"date-time":"2018-03-12T05:05:23Z","timestamp":1520831123000},"page":"1710-1720","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Diagnostic performance and impact on patient management of 68Ga-DOTA-TOC PET\/CT for detecting osteomalacia-associated tumours"],"prefix":"10.1007","volume":"45","author":[{"given":"Marie","family":"Paquet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Gauth\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jules","family":"Zhang Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Nataf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oph\u00e9lie","family":"B\u00e9lissant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Orcel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Roux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-No\u00ebl","family":"Talbot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7oise","family":"Montravers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,3,12]]},"reference":[{"key":"3971_CR1","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1056\/NEJMe030037","volume":"348","author":"TO Carpenter","year":"2003","unstructured":"Carpenter TO. Oncogenic osteomalacia\u2014a complex dance of factors. N Engl J Med. 2003;348:1705\u20138.","journal-title":"N Engl J Med"},{"key":"3971_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/00000478-200401000-00001","volume":"28","author":"AL Folpe","year":"2004","unstructured":"Folpe AL, Fanburg-Smith JC, Billings SD, Bisceglia M, Bertoni F, Cho JY, et al. Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature. Am J Surg Pathol. 2004;28:1\u201330.","journal-title":"Am J Surg Pathol"},{"key":"3971_CR3","doi-asserted-by":"publisher","first-page":"4088","DOI":"10.1210\/jc.2002-021919","volume":"88","author":"AE Nelson","year":"2003","unstructured":"Nelson AE, Bligh RC, Mirams M, Gill A, Au A, Clarkson A, et al. Clinical case seminar: fibroblast growth factor 23: a new clinical marker for oncogenic osteomalacia. J Clin Endocrinol Metab. 2003;88:4088\u201394.","journal-title":"J Clin Endocrinol Metab"},{"issue":"17","key":"3971_CR4","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1056\/NEJMoa020881","volume":"348","author":"KB Jonsson","year":"2003","unstructured":"Jonsson KB, Zahradnik R, Larsson T, White KE, Sugimoto T, Imanishi Y, et al. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med. 2003;348(17):1656\u201363.","journal-title":"N Engl J Med"},{"key":"3971_CR5","doi-asserted-by":"publisher","first-page":"3618","DOI":"10.1007\/s11999-013-3178-1","volume":"471","author":"CK Ledford","year":"2013","unstructured":"Ledford CK, Zelenski NA, Cardona DM, Brigman BE, Eward WC. The phosphaturic mesenchymal tumor: why is definitive diagnosis and curative surgery often delayed? Clin Orthop. 2013;471:3618\u201325.","journal-title":"Clin Orthop"},{"key":"3971_CR6","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1586\/eem.09.27","volume":"4","author":"EG Farrow","year":"2009","unstructured":"Farrow EG, White KE. Tumor-induced osteomalacia. Expert Rev Endocrinol Metab. 2009;4:435\u201342.","journal-title":"Expert Rev Endocrinol Metab"},{"key":"3971_CR7","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1002\/jbmr.1881","volume":"28","author":"WH Chong","year":"2013","unstructured":"Chong WH, Andreopoulou P, Chen CC, Reynolds J, Guthrie L, Kelly M, et al. Tumor localization and biochemical response to cure in tumor-induced osteomalacia. J Bone Miner Res. 2013;28:1386\u201398.","journal-title":"J Bone Miner Res"},{"key":"3971_CR8","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1210\/jc.2011-1757","volume":"96","author":"WH Chong","year":"2011","unstructured":"Chong WH, Yavuz S, Patel SM, Chen CC, Collins MT. The importance of whole body imaging in tumor-induced osteomalacia. J Clin Endocrinol Metab. 2011;96:3599\u2013600.","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"3971_CR9","doi-asserted-by":"publisher","first-page":"2711","DOI":"10.1016\/j.humpath.2013.07.016","volume":"44","author":"M Houang","year":"2013","unstructured":"Houang M, Clarkson A, Sioson L, Elston MS, Clifton-Bligh RJ, Dray M, et al. Phosphaturic mesenchymal tumors show positive staining for somatostatin receptor 2A (SSTR2A). Hum Pathol. 2013;44(12):2711\u20138.","journal-title":"Hum Pathol"},{"key":"3971_CR10","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1210\/jc.2012-3642","volume":"98","author":"RJ Clifton-Bligh","year":"2013","unstructured":"Clifton-Bligh RJ, Hofman MS, Duncan E, Sim I-W, Darnell D, Clarkson A, et al. Improving diagnosis of tumor-induced osteomalacia with gallium-68 DOTATATE PET\/CT. J Clin Endocrinol Metab. 2013;98:687\u201394.","journal-title":"J Clin Endocrinol Metab"},{"key":"3971_CR11","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/S0140-6736(02)07846-7","volume":"359","author":"SM Jan de Beur","year":"2002","unstructured":"Jan de Beur SM, Streeten EA, Civelek AC, EF MC, Uribe L, Marx SJ, et al. Localisation of mesenchymal tumours by somatostatin receptor imaging. Lancet Lond Engl. 2002;359:761\u20133.","journal-title":"Lancet Lond Engl"},{"key":"3971_CR12","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1001\/jama.294.10.1260","volume":"294","author":"SM Jan de Beur","year":"2005","unstructured":"Jan de Beur SM. Tumor-induced osteomalacia. JAMA. 2005;294:1260\u20137.","journal-title":"JAMA"},{"key":"3971_CR13","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1097\/00003072-199902000-00016","volume":"24","author":"BD Nguyen","year":"1999","unstructured":"Nguyen BD, Wang EA. Indium-111 pentetreotide scintigraphy of mesenchymal tumor with oncogenic osteomalacia. Clin Nucl Med. 1999;24:130\u20131.","journal-title":"Clin Nucl Med"},{"key":"3971_CR14","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1007\/s11307-010-0374-1","volume":"13","author":"Y Krausz","year":"2011","unstructured":"Krausz Y, Freedman N, Rubinstein R, Lavie E, Orevi M, Tshori S, et al. 68Ga-DOTA-NOC PET\/CT imaging of neuroendocrine tumors: comparison with 111In-DTPA-octreotide (OctreoScan\u00ae). Mol Imaging Biol. 2011;13:583\u201393.","journal-title":"Mol Imaging Biol"},{"key":"3971_CR15","doi-asserted-by":"publisher","first-page":"872","DOI":"10.2967\/jnumed.115.165803","volume":"57","author":"SA Deppen","year":"2016","unstructured":"Deppen SA, Blume J, Bobbey AJ, Shah C, Graham MM, Lee P, et al. 68Ga-DOTATATE compared with 111In-DTPA-octreotide and conventional imaging for pulmonary and gastroenteropancreatic neuroendocrine tumors: a systematic review and meta-analysis. J Nucl Med. 2016;57:872\u20138.","journal-title":"J Nucl Med"},{"key":"3971_CR16","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.2967\/jnumed.117.191197","volume":"58","author":"MM Graham","year":"2017","unstructured":"Graham MM, Gu X, Ginader T, Breheny P, Sunderland JJ. 68Ga-DOTATOC imaging of neuroendocrine tumors: a systematic review and metaanalysis. J Nucl Med. 2017;58:1452\u20138.","journal-title":"J Nucl Med"},{"key":"3971_CR17","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1359\/jbmr.060909","volume":"22","author":"E Hesse","year":"2007","unstructured":"Hesse E, Moessinger E, Rosenthal H, Laenger F, Brabant G, Petrich T, et al. Oncogenic osteomalacia: exact tumor localization by co-registration of positron emission and computed tomography. J Bone Miner Res. 2007;22:158\u201362.","journal-title":"J Bone Miner Res"},{"key":"3971_CR18","doi-asserted-by":"publisher","first-page":"4511","DOI":"10.1210\/jc.2010-0543","volume":"95","author":"G Haeusler","year":"2010","unstructured":"Haeusler G, Freilinger M, Dominkus M, Egerbacher M, Amann G, Kolb A, et al. Tumor-induced hypophosphatemic rickets in an adolescent boy - clinical presentation, diagnosis, and histological findings in growth plate and muscle tissue. J Clin Endocrinol Metab. 2010;95:4511\u20137.","journal-title":"J Clin Endocrinol Metab"},{"key":"3971_CR19","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1007\/s00270-016-1350-1","volume":"39","author":"M Maybody","year":"2016","unstructured":"Maybody M, Grewal RK, Healey JH, Antonescu CR, Fanchon L, Hwang S, et al. Ga-68 DOTATOC PET\/CT-guided biopsy and cryoablation with autoradiography of biopsy specimen for treatment of tumor-induced osteomalacia. Cardiovasc Intervent Radiol. 2016;39:1352\u20137.","journal-title":"Cardiovasc Intervent Radiol"},{"key":"3971_CR20","doi-asserted-by":"crossref","unstructured":"Kawai S, Ariyasu H, Furukawa Y, Yamamoto R, Uraki S, Takeshima K, et al. Effective localization in tumor-induced osteomalacia using 68Ga-DOTATOC-PET\/CT, venous sampling and 3T-MRI. Endocrinol Diabetes Metab Case Rep. 2017;2017","DOI":"10.1530\/EDM-17-0005"},{"issue":"41","key":"3971_CR21","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000001701","volume":"94","author":"L Michaud","year":"2015","unstructured":"Michaud L, Balogova S, Burgess A, Ohnona J, Huchet V, Kerrou K, et al. A pilot comparison of 18F-fluorocholine PET\/CT, ultrasonography and 123I\/99mTc-sestaMIBI dual-phase dual-isotope scintigraphy in the preoperative localization of hyperfunctioning parathyroid glands in primary or secondary hyperparathyroidism: influence of thyroid anomalies. Medicine (Baltimore). 2015;94(41):e1701.","journal-title":"Medicine (Baltimore)"},{"key":"3971_CR22","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1002\/jbmr.1642","volume":"27","author":"Y Jiang","year":"2012","unstructured":"Jiang Y, Xia W, Xing X, Silva BC, Li M, Wang O, et al. Tumor-induced osteomalacia: an important cause of adult-onset hypophosphatemic osteomalacia in China: report of 39 cases and review of the literature. J Bone Miner Res. 2012;27:1967\u201375.","journal-title":"J Bone Miner Res"},{"issue":"14","key":"3971_CR23","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.2217\/fon.14.139","volume":"10","author":"CB Johnbeck","year":"2014","unstructured":"Johnbeck CB, Knigge U, Kj\u00e6r A. PET tracers for somatostatin receptor imaging of neuroendocrine tumors: current status and review of the literature. Future Oncol. 2014;10(14):2259\u201377.","journal-title":"Future Oncol"},{"key":"3971_CR24","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1016\/j.ejrad.2013.04.006","volume":"82","author":"H Jing","year":"2013","unstructured":"Jing H, Li F, Zhuang H, Wang Z, Tian J, Xing X, et al. Effective detection of the tumors causing osteomalacia using [Tc-99m]-HYNIC-octreotide (99mTc-HYNIC-TOC) whole body scan. Eur J Radiol. 2013;82:2028\u201334.","journal-title":"Eur J Radiol"},{"key":"3971_CR25","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/cen.12426","volume":"81","author":"S Jadhav","year":"2014","unstructured":"Jadhav S, Kasaliwal R, Lele V, Rangarajan V, Chandra P, Shah H, et al. Functional imaging in primary tumour-induced osteomalacia: relative performance of FDG PET\/CT vs somatostatin receptor-based functional scans: a series of nine patients. Clin Endocrinol. 2014;81:31\u20137.","journal-title":"Clin Endocrinol"},{"issue":"8","key":"3971_CR26","doi-asserted-by":"publisher","first-page":"2925","DOI":"10.1021\/mp400040z","volume":"10","author":"C Dong","year":"2013","unstructured":"Dong C, Zhao H, Yang S, Shi J, Huang J, Cui L, et al. 99mTc-labeled dimeric octreotide peptide: a radiotracer with high tumor uptake for single-photon emission computed tomography imaging of somatostatin receptor subtype 2-positive tumors. Mol Pharm. 2013;10(8):2925\u201333.","journal-title":"Mol Pharm"},{"key":"3971_CR27","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.bone.2014.04.016","volume":"64","author":"S Breer","year":"2014","unstructured":"Breer S, Brunkhorst T, Beil FT, Peldschus K, Heiland M, Klutmann S, et al. 68Ga DOTA-TATE PET\/CT allows tumor localization in patients with tumor-induced osteomalacia but negative 111In-octreotide SPECT\/CT. Bone. 2014;64:222\u20137.","journal-title":"Bone"},{"key":"3971_CR28","doi-asserted-by":"publisher","first-page":"e6","DOI":"10.1097\/RLU.0000000000000460","volume":"40","author":"K Agrawal","year":"2015","unstructured":"Agrawal K, Bhadada S, Mittal BR, Shukla J, Sood A, Bhattacharya A, et al. Comparison of 18F-FDG and 68Ga DOTATATE PET\/CT in localization of tumor causing oncogenic osteomalacia. Clin Nucl Med. 2015;40:e6\u201310.","journal-title":"Clin Nucl Med"},{"key":"3971_CR29","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s13139-015-0328-2","volume":"49","author":"CL Ho","year":"2015","unstructured":"Ho CL. Ga68-DOTA peptide PET\/CT to detect occult mesenchymal tumor-inducing osteomalacia: a case series of three patients. Nucl Med Mol Imaging. 2015;49:231\u20136.","journal-title":"Nucl Med Mol Imaging"},{"key":"3971_CR30","doi-asserted-by":"publisher","first-page":"3575","DOI":"10.1210\/jc.2016-2052","volume":"101","author":"D El-Maouche","year":"2016","unstructured":"El-Maouche D, Sadowski SM, Papadakis GZ, Guthrie L, Cottle-Delisle C, Merkel R, et al. 68Ga-DOTATATE for tumor localization in tumor-induced osteomalacia. J Clin Endocrinol Metab. 2016;101:3575\u201381.","journal-title":"J Clin Endocrinol Metab"},{"key":"3971_CR31","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1097\/RLU.0000000000000854","volume":"40","author":"J Zhang","year":"2015","unstructured":"Zhang J, Zhu Z, Zhong D, Dang Y, Xing H, Du Y, et al. 68Ga DOTATATE PET\/CT is an accurate imaging modality in the detection of culprit tumors causing osteomalacia. Clin Nucl Med. 2015;40:642\u20136.","journal-title":"Clin Nucl Med"},{"key":"3971_CR32","doi-asserted-by":"publisher","first-page":"20160811","DOI":"10.1259\/bjr.20160811","volume":"90","author":"D Singh","year":"2017","unstructured":"Singh D, Chopra A, Ravina M, Kongara S, Bhatia E, Kumar N, et al. Oncogenic osteomalacia: role of Ga-68 DOTANOC PET\/CT scan in identifying the culprit lesion and its management. Br J Radiol. 2017;90:20160811.","journal-title":"Br J Radiol"},{"key":"3971_CR33","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1111\/cen.12822","volume":"84","author":"N Bhavani","year":"2016","unstructured":"Bhavani N, Reena Asirvatham A, Kallur K, Menon AS, Pavithran PV, Nair V, et al. Utility of gallium-68 DOTANOC PET\/CT in the localization of tumour-induced osteomalacia. Clin Endocrinol. 2016;84:134\u201340.","journal-title":"Clin Endocrinol"},{"issue":"4","key":"3971_CR34","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1530\/eje.0.1500565","volume":"150","author":"EG Lichtenauer-Kaligis","year":"2004","unstructured":"Lichtenauer-Kaligis EG, Dalm VA, Oomen SP, Mooij DM, van Hagen PM, Lamberts SW, et al. Differential expression of somatostatin receptor subtypes in human peripheral blood mononuclear cell subsets. Eur J Endocrinol. 2004;150(4):565\u201377.","journal-title":"Eur J Endocrinol"},{"key":"3971_CR35","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.bone.2005.01.001","volume":"36","author":"JL Dupond","year":"2005","unstructured":"Dupond JL, Mahammedi H, Pri\u00e9 D, Collin F, Gil H, Blagosklonov O, et al. Oncogenic osteomalacia: diagnostic importance of fibroblast growth factor 23 and F-18 fluorodeoxyglucose PET\/CT scan for the diagnosis and follow-up in one case. Bone. 2005;36:375\u20138.","journal-title":"Bone"},{"key":"3971_CR36","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1097\/RLU.0b013e3181f49e69","volume":"35","author":"G Malhotra","year":"2010","unstructured":"Malhotra G, Agrawal A, Jambhekar NA, Sarathi V, Jagtap V, Agarwal MG, et al. Interesting image. The search for primary tumor in a patient with oncogenic osteomalacia: F-18 FDG PET resolves the conundrum. Clin Nucl Med. 2010;35:896\u20138.","journal-title":"Clin Nucl Med"},{"issue":"5","key":"3971_CR37","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.7150\/thno.18068","volume":"7","author":"DL Chan","year":"2017","unstructured":"Chan DL, Pavlakis N, Schembri GP, Bernard EJ, Hsiao E, Hayes A, et al. Dual somatostatin receptor\/FDG PET\/CT imaging in metastatic neuroendocrine tumours: proposal for a novel grading scheme with prognostic significance. Theranostics. 2017;7(5):1149\u201358.","journal-title":"Theranostics"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00259-018-3971-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-018-3971-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-018-3971-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,12]],"date-time":"2019-10-12T13:32:55Z","timestamp":1570887175000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00259-018-3971-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,12]]},"references-count":37,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["3971"],"URL":"https:\/\/doi.org\/10.1007\/s00259-018-3971-x","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,12]]},"assertion":[{"value":"6 October 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinski declaration and its later amendments.Research involving human participants and\/or animals: for this type of study, formal consent is not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"This study was approved by the institutional review board; the patients gave their written consent for a subsequent use of their PET\/CT images for research purposes.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}